0 CHECKOUT

Hyperphosphatemia - Pipeline Review, H1 2015

  • ID: 3142666
  • February 2015
  • 80 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • OPKO Health, Inc.
  • Panion & Bf Biotech Inc
  • Sanofi
  • Toray Industries, Inc.
  • MORE

Hyperphosphatemia - Pipeline Review, H1 2015

Summary

This, ‘Hyperphosphatemia - Pipeline Review, H1 2015’, provides an overview of the Hyperphosphatemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hyperphosphatemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperphosphatemia and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • OPKO Health, Inc.
  • Panion & Bf Biotech Inc
  • Sanofi
  • Toray Industries, Inc.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Hyperphosphatemia Overview
Therapeutics Development
Pipeline Products for Hyperphosphatemia - Overview
Pipeline Products for Hyperphosphatemia - Comparative Analysis
Hyperphosphatemia - Therapeutics under Development by Companies
Hyperphosphatemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Hyperphosphatemia - Products under Development by Companies
Hyperphosphatemia - Companies Involved in Therapeutics Development
Astellas Pharma Inc.
AstraZeneca PLC
Medice Arzneimittel Putter GmbH & Co. KG
Mitsubishi Tanabe Pharma Corporation
OPKO Health, Inc.
Panion & Bf Biotech Inc
Sanofi
Spectrum Pharmaceuticals, Inc.
Toray Industries, Inc.
Vifor Pharma AG
Hyperphosphatemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ASP-3325 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
colestilan chloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fe-SAMMS - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fermagate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ferric citrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JPH-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
niacinamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PT-20 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RDX-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia In CKD - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SPI-014 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sucroferric oxyhydroxide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tenapanor hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TRK-390 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VS-501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VS-505 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hyperphosphatemia - Recent Pipeline Updates
Hyperphosphatemia - Dormant Projects
Hyperphosphatemia - Discontinued Products
Hyperphosphatemia - Product Development Milestones
Featured News & Press Releases
Feb 02, 2015: Ardelyx Reports Results from Phase 2b Clinical Trial Evaluating Tenapanor in Treating Hyperphosphatemia in Chronic Kidney Disease Patients on Hemodialysis
Jan 27, 2015: Velphoro receives Swissmedic approval for the treatment of hyperphosphatemia in adult patients with chronic kidney disease on dialysis
Jan 09, 2015: Keryx Biopharmaceuticals Turns to Veeva Commercial Cloud to Support First FDA-Approved Product Launch
Dec 04, 2014: Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Auryxia (ferric citrate) Covering Orally Administrable Forms
Nov 19, 2014: New Drug Application Submitted For PA21 (development code) For Treatment Of Hyperphosphatemia
Nov 17, 2014: Keryx Biopharmaceuticals Announces Trade Name Auryxia for Ferric Citrate
Nov 15, 2014: Keryx Biopharmaceuticals Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension Study
Oct 23, 2014: Ardelyx's Tenapanor Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2014
Oct 01, 2014: Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Ferric Citrate Covering Orally Administrable Forms
Sep 05, 2014: Keryx Biopharmaceuticals Receives FDA Approval of Ferric Citrate, a New, Oral Iron-Based Treatment for Dialysis Patients With Hyperphosphatemia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Hyperphosphatemia, H1 2015
Number of Products under Development for Hyperphosphatemia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Hyperphosphatemia - Pipeline by Astellas Pharma Inc., H1 2015
Hyperphosphatemia - Pipeline by AstraZeneca PLC, H1 2015
Hyperphosphatemia - Pipeline by Medice Arzneimittel Putter GmbH & Co. KG, H1 2015
Hyperphosphatemia - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015
Hyperphosphatemia - Pipeline by OPKO Health, Inc., H1 2015
Hyperphosphatemia - Pipeline by Panion & Bf Biotech Inc, H1 2015
Hyperphosphatemia - Pipeline by Sanofi, H1 2015
Hyperphosphatemia - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015
Hyperphosphatemia - Pipeline by Toray Industries, Inc., H1 2015
Hyperphosphatemia - Pipeline by Vifor Pharma AG, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Hyperphosphatemia Therapeutics - Recent Pipeline Updates, H1 2015
Hyperphosphatemia - Dormant Projects, H1 2015
Hyperphosphatemia - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Hyperphosphatemia, H1 2015
Number of Products under Development for Hyperphosphatemia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Astellas Pharma Inc.
AstraZeneca PLC
Medice Arzneimittel Putter GmbH & Co. KG
Mitsubishi Tanabe Pharma Corporation
OPKO Health, Inc.
Panion & Bf Biotech Inc
Sanofi
Spectrum Pharmaceuticals, Inc.
Toray Industries, Inc.
Vifor Pharma AG

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Pfizer Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S